1-5 of 5
Indu Lal
Close
Sort by
Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani
Journal: Blood
Blood (2022) 140 (Supplement 1): 3728–3730.
https://doi.org/10.1182/blood-2022-167772
Published: 2022
Journal Articles

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

Lisa Johnson, Yajia Zhang, Biao Li, Lisa Aviles, Indu Lal, Giri Ramsingh, Naval Daver, Paresh Vyas, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6934–6935.
https://doi.org/10.1182/blood-2022-160337
Published: 2022
Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-134437
Published: 2020
Journal Articles

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Clinical Trials & Observations
David Miklos, Corey S. Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Stephen Chang, Indu Lal, Jason Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski
Journal: Blood
Blood (2017) 130 (21): 2243–2250.
https://doi.org/10.1182/blood-2017-07-793786
Published: 2017
Includes: Supplemental data
Journal Articles

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

David Miklos, MD, Corey S. Cutler, MD MPH, Mukta Arora, MD, Edmund K. Waller, MD PhD FACP, Madan Jagasia, MD MBBS, MS, Iskra Pusic, MD, Mary E. Flowers, MD, Aaron C. Logan, MD PhD, Ryotaro Nakamura, MD, Bruce R. Blazar, MD, Yunfeng Li, PhD, Indu Lal, MD, Jason Dubovsky, PhD, Danelle F. James, MD, Lori Styles, MD, Samantha Jaglowski, MD PhD
Journal: Blood
Blood (2016) 128 (22): LBA-3.
https://doi.org/10.1182/blood.V128.22.LBA-3.LBA-3
Published: 2016